Anthony J Paravati1, Peter G Hawkins1, Amanda N Martin2, Gina Mansy1, Doug A Rahn1, Sunil J Advani1, Jeremy Hoisak1, Irena Dragojevic1, Peter J Martin3, Charles J Miller4, Parag Sanghvi5. 1. Department of Radiation Medicine and Applied Sciences, University of California San Diego Moores Cancer Center, La Jolla, California. 2. Keck School of Medicine at University of Southern California, Los Angeles, California. 3. Department of Otolaryngology, Kaiser Permanente, San Diego, San Diego, California. 4. Department of Dermatology, Kaiser Permanente, San Diego, San Diego, California. 5. Department of Radiation Medicine and Applied Sciences, University of California San Diego Moores Cancer Center, La Jolla, California. Electronic address: psanghvi@ucsd.edu.
Abstract
PURPOSE: To retrospectively analyze clinical and cosmetic outcomes in patients treated for nonmelanoma skin cancer (NMSC) with high-dose-rate (HDR) electronic brachytherapy (EBT) using surface applicators. METHODS AND MATERIALS: We identified 127 patients who had 154 NMSC lesions, 149 of which were basal cell carcinoma, treated with HDR EBT at our institution between July 2012 and March 2014. Lesions were treated to 40 Gy in 8 fractions. Local control, acute toxicity, late toxicity, and cosmetic outcomes were analyzed retrospectively. Acute and late toxicities were graded using the Common Terminology Criteria for Adverse Events, version 4.0. Cosmetic outcomes were graded using a standard scale based on the Radiation Therapy Oncology Group and European Organization for Research and Treatment of Cancer Late Radiation Morbidity Scoring Schema. RESULTS: Median (range) follow-up from completion of treatment was 16.1 (3.4-34.8 months). The overall crude recurrence rate was 1.3% (n = 2). Grade 0 to 1 acute radiation dermatitis was observed in 52.6% of treated lesions (n = 81), grade 2 in 34.4% (n = 53), and grade 3 in 13.0% (n = 20). No acute toxicity greater than grade 3 was observed and all acute toxic events resolved after treatment. Grade 0 to 1 late toxicity was observed in 94.2% of cases (n = 145), and grade 2 in 5.8% (n = 9). No late toxicity greater than grade 2 was observed. Across the 152 controlled lesions, cosmetic results were excellent in 94.2% of treated lesions (n = 145), good in 3.3% (n = 5), fair in 0.7% (n = 1), and poor in 0.7% (n = 1). CONCLUSIONS: HDR EBT confers promising local control, minimal toxicity, and excellent cosmesis in our institutional experience. It should be considered ideal for NMSC of the head and neck, particularly for basal cell carcinoma involving central facial locations where surgical cosmesis may be inferior.
PURPOSE: To retrospectively analyze clinical and cosmetic outcomes in patients treated for nonmelanoma skin cancer (NMSC) with high-dose-rate (HDR) electronic brachytherapy (EBT) using surface applicators. METHODS AND MATERIALS: We identified 127 patients who had 154 NMSC lesions, 149 of which were basal cell carcinoma, treated with HDR EBT at our institution between July 2012 and March 2014. Lesions were treated to 40 Gy in 8 fractions. Local control, acute toxicity, late toxicity, and cosmetic outcomes were analyzed retrospectively. Acute and late toxicities were graded using the Common Terminology Criteria for Adverse Events, version 4.0. Cosmetic outcomes were graded using a standard scale based on the Radiation Therapy Oncology Group and European Organization for Research and Treatment of Cancer Late Radiation Morbidity Scoring Schema. RESULTS: Median (range) follow-up from completion of treatment was 16.1 (3.4-34.8 months). The overall crude recurrence rate was 1.3% (n = 2). Grade 0 to 1 acute radiation dermatitis was observed in 52.6% of treated lesions (n = 81), grade 2 in 34.4% (n = 53), and grade 3 in 13.0% (n = 20). No acute toxicity greater than grade 3 was observed and all acute toxic events resolved after treatment. Grade 0 to 1 late toxicity was observed in 94.2% of cases (n = 145), and grade 2 in 5.8% (n = 9). No late toxicity greater than grade 2 was observed. Across the 152 controlled lesions, cosmetic results were excellent in 94.2% of treated lesions (n = 145), good in 3.3% (n = 5), fair in 0.7% (n = 1), and poor in 0.7% (n = 1). CONCLUSIONS: HDR EBT confers promising local control, minimal toxicity, and excellent cosmesis in our institutional experience. It should be considered ideal for NMSC of the head and neck, particularly for basal cell carcinoma involving central facial locations where surgical cosmesis may be inferior.
Authors: Anna O Likhacheva; Phillip M Devlin; Shervin M Shirvani; Christopher A Barker; Phillip Beron; Ajay Bhatnagar; Stephen W Doggett; Lawrence Hochman; Charles Hsu; Michael Kasper; Martin Keisch; Subhakar Mutyala; Bradley Prestidge; Silvia Rodriguez Villalba; Vershalee Shukla; Srinath Sundararaman; Mitchell Kamrava Journal: Brachytherapy Date: 2016-11-28 Impact factor: 2.362
Authors: Sofian Benkhaled; Dirk Van Gestel; Carolina Gomes da Silveira Cauduro; Samuel Palumbo; Veronique Del Marmol; Antoine Desmet Journal: Front Med (Lausanne) Date: 2022-06-27
Authors: Rosa Ballester-Sánchez; Olga Pons-Llanas; Cristian Candela-Juan; Francisco Javier Celada-Álvarez; Christopher A Barker; Alejandro Tormo-Micó; Jose Pérez-Calatayud; Rafael Botella-Estrada Journal: J Contemp Brachytherapy Date: 2016-01-28
Authors: Rosa Ballester-Sánchez; Olga Pons-Llanas; Cristian Candela-Juan; Blanca de Unamuno-Bustos; Francisco Javier Celada-Alvarez; Alejandro Tormo-Mico; Jose Perez-Calatayud; Rafael Botella-Estrada Journal: J Contemp Brachytherapy Date: 2017-06-05